What do we want to develop to help patients around the world?

  • Health care budget are out of control related to high in-patient treatment costs
  • Aging populations combined with reduced bed-stock is causing massive pressure on already constraint hospital resources
  • Hospitals are a dangerous breeding ground for resistant microorganisms
  • In American alone, the Centers for Disease Control (CDC) estimates that nosocomial infections account for an estimated 1.7 million infections and 99,000 associated deaths each year (4)
  • Across the globe numbers of deaths due to anti-microbial resistance (AMR) are estimated to reach 10 mio deaths annually if urgent action is not taken, therefore adopted treatment regiments like continuous infusion is necessary

These issues are driving the need for increased community-based care currently resulting in ~1 million outpatient parenteral antibiotic therapy episodes worldwide every year.

  • However the rate of expansion is severely limited by the lack of efficient and scalable solutions
  • Current technologies are cumbersome, labor-intensive (requiring compounding and frequent nursing supervision), error prone and often rely on easier to administer untargeted antibiotic therapies, which drive resistance.

Our innovative solution provides the simplicity and efficiency of use which is required for large-scale increases in community based infectious diseases management, with potential to impact other therapy areas in a similarly significant manner.